Carbohydrates in Peptide and Protein Design - Peptide and Protein Design for Biopharmaceutical Applications - page 199

[15] K. J. Jensen, M. Meldal and K. Bock, Glycosylation of phenols: Preparation of 1,2-cis
and 1,2-trans glycosylated tyrosine derivatives to be used in solid-phase glycopeptide
synthesis, J. Chem. Soc. Perkin Trans . 1, 2119-2129 (1993).
[16] D. Pinzani, A. M. Papini, M. E. Vallecchi, M. Chelli, M. Ginanneschi, G. Rapi,
L. Quartara, R. Patacchini, C. A. Maggi and F. M. Arcamone, Glycosyl derivatives of
NK2 tachykinin receptor antagonists, Bioorg. Med. Chem. Lett ., 6, 367-372 (1996).
[17] R.-M. Catalioto, M. Criscuoli, P. Cucchi, A. Giachetti, D. Giannotti, S. Giuliani,
A. Lecci, A. Lippi, R. Patacchini, L. Quartara, A. R. Renzetti, M. Tramontana,
F. Arcamone and C. A. Maggi, MEN 11420 (Nepadutant), a novel glycosylated
bicyclic peptide tachykinin NK 2 receptor antagonist, Brit. J. Pharmacology , 123,
81-91 (1998).
[18] L. Varga, S. Horvat, C. Lemieux and P. W. Schiller, Synthesis and biological activity
of some glucose-enkephalin conjugates, Int. J. Peptide Protein Res ., 30, 371-378
(1987).
[19] M. Skuric, J. Horvat, S. Horvat, N. N. Chung and P. W. Schiller, Acetylated
glucopyranosyl esters of enkephalins, Int. J. Peptide Protein Res ., 43, 402-409
(1994).
[20] L. Otvos, M. Terrasi, S. Cascio, M. Cassone, G. Abbadessa, F. De Pascali, L. Scolaro,
D. Knappe, M. Stawikowski, P. Cudic, J. D. Wade, R. Hoffmann and E. Surmacz,
Development of a pharmacologically improved peptide agonist of the leptin receptor,
Biochim. Biophys. Acta ., 1783, 1745-1754 (2008).
[21] M. T. McQuillan, Somatostatin , vol. 2, Eden, Quebec, 1980.
[22] C. H. S. McIntosh, Gastrointestinal somatostatin: Distribution, secretion and phy-
siological significance, Life Sci ., 37, 2043-2058 (1985).
[23] C.-J. Su, J. W. White, W. H. Li, C.-C. Luo, M. L. Frazier, G. F. Saunders and
L. Chan, Structure and evolution of somatostatin genes, Mol. Endocrinol , 2,
209-216 (1988).
[24] P. Brazeau, W. Vale, R. Burgus, J. Rivier and R. Guillemin, Inhibition of growth
hormone secretion in the rat by synthetic somatostatin, Science , 179, 77-79 (1973).
[25] D. Koerker, W. Ruch, E. Chideckel, J. Palmer, C. Goodner, J. Ensinck and C. Gale,
Somatostatin: Hypothalamic inhibitor of the endocrine pancreas, Science , 184,
482-484 (1974).
[26] J. Polak, A. Pearse, L. Grimelius, S. R. Bloom and A. Arimura, Growth-hormone
release-inhibiting hormone in gastrointestinal and pancreatic D -cells, Lancet , 1,
1220-1222 (1975).
[27] S. J. Konturek, J. Tasler, W. Obtulowicz, D. H. Coy and A. V. Schally, Effect of
growth hormone-release inhibiting hormone on hormones stimulating exocrine pan-
creatic-secretion, J. Clin. Invest ., 58, 1-6 (1976).
[28] Y. Yamada, S. R. Post, K. Wong, H. Tager, G. I. Bell and S. Seino, Cloning and
functional characterization of a family of human and mouse somatostatin receptors
expressed in brain, gastrointestinal trcat, and kidney, PNAS , 89, 251-255 (1992).
[29] K. Raynor, A. O'Carroll, H. Kong, K. Yasuda, L. C. Mahan, G. I. Bell and T. Reisine,
Characterization of cloned somatostatin receptors SSTR4 and SSTR5, Mol.

Pharmacol ., 44, 385-392 (1993).
[30] K. Raynor, W. A. Murphy, D. H. Coy, J. E. Taylor, J.-P. Moreau, K. Yasuda,
M. I. Bell and T. Reisine, Cloned somatostatin receptors - Identification of sub-
type-selective peptides and demonstration of high-affinity binding of linear peptides,
Mol. Pharmacol ., 43, 838-844 (1993).